Is Semaglutide Legal in Australia? (2026 Research Status)
Here’s a number that reshaped the conversation around metabolic health: in the STEP 1 trial, adults with overweight or obesity receiving once-weekly semaglutide 2.4 mg experienced a mean body weight change of approximately −14.9% over 68 weeks, compared to −2.4% with placebo Wilding et al., 2021. That single result sent demand for semaglutide soaring worldwide — and with it, a wave of confusion about where the compound is legal, how to access it, and what the rules actually are.
If you’re in Australia, you’ve likely encountered contradictory information. Pharmacies have posted shortage notices. News outlets have reported on regulatory crackdowns. Online forums are full of speculation. So what’s actually true?
This guide breaks down the current legal status of semaglutide in Australia as of 2026 — what’s approved, what’s restricted, and what the research landscape looks like — so you can make informed decisions grounded in evidence, not hype.
What Is Semaglutide?
Semaglutide is a synthetic analogue of the human glucagon-like peptide-1 (GLP-1) hormone. GLP-1 is an incretin — a gut-derived signalling molecule released after eating that helps regulate blood glucose and appetite. Semaglutide is engineered to resist rapid degradation by the enzyme DPP-4, giving it an extended half-life of roughly one week and allowing once-weekly dosing.
For a deeper dive into the pharmacology, mechanisms, and research history of this compound, see our full semaglutide compound profile.
Is Semaglutide Legal in Australia?
Yes — but with significant conditions. Semaglutide is not a banned substance in Australia. It is, however, classified as a Schedule 4 (S4) Prescription Only Medicine under the Poisons Standard (also known as the SUSMP). This means:
- You cannot purchase it over the counter.
- You cannot legally obtain it without a valid prescription from an Australian-registered medical practitioner.
- It is subject to the same regulatory controls as other prescription-only medications.
The Therapeutic Goods Administration (TGA) — Australia’s medicines regulator — has approved specific semaglutide products for defined therapeutic indications. Those approvals carry weight: they mean the product has been evaluated for quality, safety, and efficacy within a particular clinical context.
TGA-Approved Semaglutide Products
As of 2026, two primary branded semaglutide products hold TGA registration:
Ozempic (semaglutide, lower doses)
Ozempic contains semaglutide at doses of 0.25 mg, 0.5 mg, and 1 mg per injection. It is approved for use in adults with type 2 diabetes mellitus to improve glycaemic control. In the STEP 2 trial, semaglutide 2.4 mg once weekly was shown to significantly reduce HbA1c and body weight in adults with type 2 diabetes and overweight or obesity compared to placebo Davies et al., 2021, though the lower doses approved for Ozempic in Australia are specifically indicated for glycaemic management rather than weight loss per se.
Wegovy (semaglutide, higher doses)
Wegovy contains semaglutide at doses up to 2.4 mg per injection and is approved for chronic weight management in adults with a BMI of 30 kg/m² or above (or 27 kg/m² with at least one weight-related comorbidity), used in conjunction with a reduced-calorie diet and increased physical activity. This is the product most directly associated with the weight-management research outcomes that have driven public interest.
The distinction matters. A doctor prescribing Ozempic off-label for weight loss is operating outside the TGA-approved indication for that product — while prescribing Wegovy for the same purpose is within the approved label. This nuance often gets lost in public discussion.
The Compounding Question
One of the most confusing aspects of the Australian semaglutide landscape involves compounded versions. Compounding pharmacies prepare customised medications for individual patients under prescription. For a period, some Australian compounding pharmacies were producing compounded semaglutide preparations, often at lower prices than the branded products.
However, the TGA has taken an increasingly firm stance on this practice. Key points:
- Semaglutide is not currently approved as an active ingredient for compounding in the way that some other peptides or hormones may be. The TGA has issued warnings about compounded semaglutide, citing concerns about quality assurance, sterility, and dose accuracy.
- Products sourced from compounding pharmacies do not undergo the same quality testing as TGA-registered medicines.
- The regulatory environment around compounded peptides in Australia has tightened significantly. For a broader look at the evolving legal status of peptide compounds, see our guide: Are Peptides Legal Again? The 2026 Guide.
If you encounter compounded semaglutide at a price that seems too good to be true, that’s a signal worth paying attention to. The research consistently shows that the quality of a pharmaceutical preparation matters — substandard dosing or contamination can introduce risks that don’t appear in clinical trial data, where the compound is manufactured under strict quality controls.
Importation Rules
Australia’s Personal Importation Scheme (PIS) allows individuals to import certain prescription medications for personal use under specific conditions. However, several important constraints apply:
- The medication must be for a legitimate medical condition for which the individual is under treatment.
- It must not be a prohibited import under Australian customs law.
- A valid Australian prescription is typically required.
- Quantities are generally limited to a maximum of three months’ supply per importation.
- The product must be declared to customs.
Importing semaglutide from overseas without a valid Australian prescription, or importing compounded products from unregulated suppliers, may breach both the Therapeutic Goods Act 1989 and the Customs Act 1901. Penalties can be significant.
The Supply Shortage Problem
Australia has experienced intermittent supply shortages of semaglutide products since 2022, driven by a global surge in demand. These shortages have created knock-on effects:
- Some patients with type 2 diabetes who rely on Ozempic for glycaemic control have struggled to access their prescribed medication.
- Some individuals have turned to unregulated online sources — a practice that carries serious risks. Products sold through these channels may be counterfeit, contaminated, incorrectly dosed, or stored improperly.
- Shortages have also fuelled demand for compounded alternatives, which — as discussed above — exist in a regulatory grey zone.
If you’re looking for legitimate pathways to access semaglutide in Australia, we’ve put together a detailed resource: Where to Buy Semaglutide in 2026.
What Does the Research Tell Us?
It’s worth stepping back from the regulatory questions to consider what the clinical evidence actually shows — and its limitations.
The STEP (Semaglutide Treatment Effect in People with Obesity) clinical trial programme is the most extensive body of evidence on semaglutide’s effects on body weight. Across multiple trials, the data suggest that semaglutide 2.4 mg may support meaningful reductions in body weight when used alongside dietary and lifestyle interventions. The STEP 5 trial extended these findings, indicating that sustained weight management effects may be achievable over a two-year treatment period Garvey et al., 2022.
However, several important caveats apply:
- Individual responses vary. Not all participants in clinical trials experienced the same degree of weight change. The figures reported are group averages.
- Side effects are common. Gastrointestinal events — including nausea, vomiting, diarrhoea, and constipation — were frequently reported in trial populations, particularly during dose titration.
- Long-term data beyond two years remain limited. Most published trials have follow-up periods of 68 to 104 weeks.
- Weight regain after discontinuation is a documented concern. Research suggests that stopping semaglutide may lead to partial or substantial regain of lost weight over time.
None of this is a claim about what semaglutide will or won’t do for any individual. It is context — the kind of context that helps you interpret headlines and make informed conversations with your healthcare provider.
Where Things Stand in 2026
To summarise the current Australian landscape:
| Status | Detail |
|---|---|
| Legal status | Schedule 4 — Prescription Only |
| TGA-approved products | Ozempic (type 2 diabetes), Wegovy (weight management) |
| Compounded semaglutide | TGA has raised significant quality and regulatory concerns |
| Importation | Permitted under Personal Importation Scheme with valid prescription and quantity limits |
| Supply | Intermittent shortages continue |
| Research base | Robust short-to-medium-term data; long-term data still emerging |
The legal framework in Australia is clear in principle: semaglutide is a prescription medicine, not a supplement, not an over-the-counter product, and not a grey-market research chemical. The challenge lies in navigating access — and in filtering the legitimate science from the noise.
Frequently Asked Questions
Can I buy semaglutide in Australia without a prescription?
No. Semaglutide is classified as a Schedule 4 (Prescription Only) medicine in Australia. You need a valid prescription from an Australian-registered medical practitioner to obtain it legally through a pharmacy.
Is compounded semaglutide legal in Australia?
The legality of compounded semaglutide is a nuanced and evolving area. The TGA has expressed concerns about compounded semaglutide products, and regulatory guidance has tightened. If you’re considering this route, it’s worth understanding the risks and the current regulatory position — our article on peptide legality in 2026 covers this in more detail.
What’s the difference between Ozempic and Wegovy?
Both contain semaglutide, but they are approved for different indications and at different dose ranges. Ozempic (lower doses) is TGA-approved for type 2 diabetes, while Wegovy (up to 2.4 mg) is approved for chronic weight management in eligible adults. They are distinct products with separate registrations.
Can I import semaglutide from overseas?
Australia’s Personal Importation Scheme may allow you to import prescription medicines for personal use, subject to specific conditions — including holding a valid Australian prescription and meeting quantity limits. Importing without proper documentation or from unregulated sources may violate Australian law.
Does research support semaglutide for long-term use?
Clinical trials such as STEP 5 suggest that semaglutide may support sustained weight management over a two-year treatment period Garvey et al., 2022. However, long-term data beyond this window are still emerging, and individual outcomes can vary. This is a question best discussed with a qualified healthcare provider who understands your specific circumstances.
